Eléments de l'association

	Ignace Vergote	13
	Carboplatin (adverse effects)	2
	Ignace Vergote *Sauf* Carboplatin (adverse effects)"	11
	Carboplatin (adverse effects) *Sauf* Ignace Vergote"	0
	Ignace Vergote Et Carboplatin (adverse effects)	2
	Ignace Vergote Ou Carboplatin (adverse effects)	13
	*Corpus*	3114

List of bibliographic references

Number of relevant bibliographic references: 2.

Ident.	Authors (with country if any)	Title
000919	Chee Khoon Lee [Australie] ; Sarah Lord [Australie] ; Tami Grunewald [Australie] ; Val Gebski [Australie] ; Anne-Claire Hardy-Bessard [France] ; Jalid Sehouli [Allemagne] ; Kathrine Woie [Norvège] ; Mark Heywood [Canada] ; Christian Schauer [Autriche] ; Ignace Vergote [Belgique] ; Giovanni Scambia [Italie] ; Annamaria Ferrero [Italie] ; Philipp Harter [Allemagne] ; Eric Pujade-Lauraine [France] ; Michael Friedlander [Australie]	Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial.
000A00	Sven Mahner [Allemagne] ; Werner Meier [Allemagne] ; Andreas Du Bois [Allemagne] ; Chris Brown [Australie] ; Domenica Lorusso [Italie] ; Tiziana Dell'Anna [Italie] ; Jacques Cretin [France] ; Hanne Havsteen [Danemark] ; Paul Bessette [Canada] ; Alain G. Zeimet [Autriche] ; Ignace Vergote [Belgique] ; Paul Vasey [Australie] ; Eric Pujade-Lauraine [France] ; Laurence Gladieff [France] ; Annamaria Ferrero [Italie]	Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024